Santhera Pharmaceuticals AG, of Liestal, Switzerland, said the Swiss Agency for Therapeutic Products accepted for review the firm's marketing authorization application for Raxone (idebenone) for the treatment of Duchenne muscular dystrophy in patients with respiratory function decline not taking concomitant glucocorticoids.